About (E2-independent) E3 ubiquitin-conjugating enzyme FATS
(E2-independent) E3 ubiquitin-conjugating enzyme FATS (C10orf90) is a protein
from Homo sapiens identified by UniProt accession
Q96M02, 699 residues long.
MolForge cross-references it against 0 known binders and
40 disease associations.
Target properties
| Protein name | (E2-independent) E3 ubiquitin-conjugating enzyme FATS |
|---|
| UniProt accession | Q96M02 |
|---|
| Gene | C10orf90 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 699 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96M02-F1 | alphafold | PREDICTED | 46.91 | — |
Amino-acid sequence (699 residues)
MLKLSGEGLR DSYHSRRDQI ALKNLQSDVT EAKSDFTKET LASQNTKMIS SIVISQMIDE NKSRENRASL PLPCAIAQSR AHHAKQSLAN RSGVNIHRAF ALLPGRLGIP APSDERGPEA ELPPKEERPC GGPRRGFASI TITARRVGPP ARALVWGTAG DSLCPKCRAE DTLFQAPPAL ANGAHPGRHQ RSFACTEFSR NSSVVRLKVP EAHTGLCERR KYWVTHADDK ETSFSPDTPL SGKSPLVFSS CVHLRVSQQC PDSIYYVDKS LSVPIEPPQI ASPKMHRSVL SLNLNCSSHR LTADGVDGLV NREPISEALK QELLEGDQDL VGQRWNPGLQ ESHLKETPSL RRVHLGTGAC PWSGSFPLEN TELANVGANQ VTVRKGEKDH TTHCHASDHA NQLSIHIPGW SYRAVHTKVF SGSSKRQQGE VCMTVSAPPV EQKPTRHFLP IGDSSPSDDC LSRDLSEPTE RRHQSFLKPR ILFPGFLCPL QDVCASLQED NGVQIESKFP KGDYTCCDLV VKIKECKKSE DPTTPEPSPA APSPAPRDGA GSPGLSEDCS ESQQTPARSL TLQEALEVRK PQFISRSQER LKKLEHMVQQ RKAQRKEDLR QKQSLLPIRT SKKQFTIPHP LSDNLFKPKE RCISEKEMHM RSKRIYDNLP EVKKKKEEQR KRVILQSNRL RAEVFKKQLL DQLLQRNAV
Explore (E2-independent) E3 ubiquitin-conjugating enzyme FATS with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets